Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NYMXF Alzheimer's treatment! -- Ignore unavailable to you. Want to Upgrade?

To: Demetre Deliyanakis who wrote (118)	8/7/1998 7:51:00 AM
From: Ron	Respond to of 132

Stock will move up. It should. Nymox says Alzheimer's drug promising ROCKVILLE, Md., Aug 6 (Reuters) - Nymox Pharmaceutical Corp. (NMX.M - news) said on Thursday that experimental studies on its drug candidate for Alzheimer's disease have yielded promising results, and that it plans to target the drug for human testing in less than a year. Nymox designed the lead compound NXD2858 in the drug to inhibit the formation of Alzheimer plaques from spherons, balls of protein found in the brain, and slow down or arrest the progression of the disease. New studies illustrate that the drug is orally bioavailable, has good blood-brain penetration and shows no evidence of toxicity or significant potential side effects, the company said. ''We are very excited by these positive developments,'' said Dr. Paul Averback, chief executive of Nymox. ''...we believe that our spheron-based therapeutic program has unique potential to modify this major disease problem (Alzheimer's). We are particularly pleased about our drug candidate's lack of toxicity thus far.'' Averback said Nymox have shown that spherons satisfy 20 criteria of validity implicating them as the potential cause of AD. He cited studies done by Nymox and other laboratories.